Clinical Trial Update: Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial comparing a tablet formulation of NNC0123-0000-0338 with insulin glargine in adults with Type 2 diabetes on oral antidiabetic therapy; study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• NNC0123-0000-0338

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED